

JC18 Rec'd PCT/PTO 0 9 1

FORM PTÖ-1390
(REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

146.1365

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/831804

INTERNATIONAL APPLICATION NO.

PCT/FR99/02739

INTERNATIONAL FILING DATE

November 9, 1999

PRIORITY DATE CLAIMED

November 10, 1998

TITLE OF INVENTION

CANDIDA ALBICANS tflIIIA GENE (CatflIIIA) AND THE CODED CATflIIIA PROTEIN

APPLICANT(S) FOR DO/EO/US

F. BORDON-PALLIER et al

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). Unexecuted
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: PCT/IB/306; International Preliminary Examination Report in English

JG18 Rec'd PCT/PTO 09 MAY 2001

U.S. APPLICATION NO. (if known, see 37 CFR 1.53) 09/831804		INTERNATIONAL APPLICATION NO. PCT/FR99/02739		ATTORNEY'S DOCKET NUMBER 146.1365	
--	--	---	--	--------------------------------------	--

17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$970.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$760.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;">\$1000.00</div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;">\$ 1000.00</div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;">\$</div>	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				<div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;">\$</div>	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	25 - 20 =	5	X \$18.00	\$ 90.00	
Independent claims	- 3 =		X \$78.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$1090.00	
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$1090.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$1090.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	
TOTAL FEES ENCLOSED =				\$1090.00	
				Amount to be: refunded	\$
				charged	\$

a. ☒ PTO FORM 2038 is enclosed A check in the amount of to cover the above fees is enclosed.


b. ☐ Please charge my Deposit Account No. in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-2275. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Bierman, Muserlian and Lucas
 600 Third Avenue
 New York, NY 10016


 SIGNATURE
Charles A. Muserlian
 NAME
19,683
 REGISTRATION NUMBER

146.1365

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: : PCT Date: 11/9/99
F. BORDON-PALLIER et al :
PCT No.: PCT/FR99/02739 :
Filed: Concurrently Herewith :
For: CANDIDA...CATFIIIA PROTEIN :

600 Third Avenue
New York N.Y. 10016

PRELIMINARY AMENDMENT

Asst. Commissioner for Patents
Washington, D.C. 20231

Sir:

Please amend this application as follows:

IN THE SPECIFICATION:

Page 1, before line 1, insert

--This application is a 371 of PCT/FR99/02739 filed November
9, 1999.--

IN THE CLAIMS:

Claim 5 (amended) DNA sequence as defined in claim 1 wherein
this DNA sequence is that of the CatfIIIA gene coding for a protein
having the biological function of transcription factor of Candida
albicans CATFIIIA containing the nucleotide sequence SEQ ID No: 1.

Claim 7 (amended) DNA sequence of the CatfIIIA gene according
to claim 5 coding for the amino acid sequence SEQ ID No: 3 (412
AA).

Claim 8 (amended) DNA sequence coding for the transcription
factor CATFIIIA according to claim 5 as well as DNA sequences which

hybridize with it and/or have a significant homology with this sequence or fragments of it and having the same function.

Claim 9 (amended) DNA sequence according to claim 5 comprising modifications introduced by suppression, insertion and/or substitution of at least one nucleotide coding for a protein having the same biological activity as the transcription factor CATFIIIA.

Claim 10 (amended) DNA sequence according to claim 5 as well as the DNA sequences which have a nucleotide sequence homology of at least 50% or at least 60% and preferably at least 70% with the said DNA sequence.

Claim 11 (amended) DNA sequence according to claim 5 as well as the DNA sequences which code for a protein with a similar function the AA sequence of which has a homology of at least 40% and in particular 45% or at least 50%, rather at least 60% and preferably at least 70% with the AA sequence coded by the said DNA sequence.

Claim 12 (amended) Polypeptide having the transcription factor function CATFIIIA and having the amino acid sequence SEQ ID No: 3 coded by the DNA sequence according to claim 5 and the analogues of this polypeptide.

Claim 13 (amended) Process for the preparation of the recombinant protein CATFIII having the amino acid sequence SEQ ID No: 3 comprising expression of the DNA sequence according to claim 5 in an appropriate host then isolation and purification of the said recombinant protein.

Claim 14 (amended) Expression vector containing the DNA sequence according to claim 5.

Claim 27 (amended) Kit for the diagnosis of fungal infections comprising a DNA sequence as defined in claim 5 or a sequence having a similar function or a functional fragment of this sequence, the polypeptide coded by this sequence or a polypeptide fragment having the same function or an antibody directed against such a polypeptide coded by this DNA sequence or against a fragment of this polypeptide.

Cancel claims 20, 21, 23 and 26 and add the following claims:

--28. A method of treating fungal infections in warm-blooded animals comprising administering to warm-blooded animals in need thereof an antifungally effective amount of a product produced by the process of claim 19.


29. A method of treating diseases caused by Candida albicans yeast in warm-blooded animals comprising administering to warm-blooded animals in need thereof a composition produced by the CATfIIIA gene or the transcription factor coded by the said gene of claim 5 in an amount sufficient to treat said diseases.--

REMARKS

The amendment is submitted to insert reference to the PCT

application, to remove multiple dependency from the claims and to provide proper method of use claims. Marked up copies of the amended claims are filed herewith.

Respectfully submitted,
Bierman, Muserlian and Lucas

By: 
Charles A. Muserlian #19,683
Attorney for Applicants
Tel.# (212) 661-8000

CAM:ds
Enclosures

CLAIMS

- 1) Isolated polynucleotide containing a nucleotide sequence chosen from the following group:
 - 5 a) a polynucleotide having at least 50 % or at least 60 % and preferably at least 70 % similarity with a polynucleotide coding for a polypeptide with the transcription factor function and having an amino acid sequence homologous with the sequence SEQ ID N°3.
 - 10 b) a complementary polynucleotide of polynucleotide a).
 - c) a polynucleotide comprising at least 15 consecutive bases of the polynucleotide defined in a) and b).
- 2) Polynucleotide according to claim 1 in that this polynucleotide is a DNA.
- 15 3) Polynucleotide according to claim 1 in that this polynucleotide is an RNA.
- 4) Polynucleotide as defined in claim 2 comprising the nucleotide sequence SEQ ID N°1
- 5) DNA sequence as defined in claims 1, 2 ^{wherein} and 4 characterized
 - 20 ~~in that~~ this DNA sequence is that of the CATfIIIA gene coding for a protein having the biological function of transcription factor of Candida albicans CATfIIIA containing the nucleotide sequence SEQ ID N°1
 - 6) DNA sequence according to claim 5 having the sequence
 - 25 starting at nucleotide 720 and finishing at nucleotide 1955 of SEQ ID N°1.
 - 7) DNA sequence of the CATfIIIA gene according to claim 5 ~~or~~ ^{coding} for the amino acid sequence SEQ ID N°3 (412 AA).
 - 8) DNA sequence coding for the transcription factor CATfIIIA
 - 30 according to claims 5 ~~to 7~~ as well as DNA sequences which hybridize with it and/or have a significant homology with this sequence or fragments of it and having the same function.
 - 9) DNA sequence according to claims 5 ~~to 8~~ comprising
 - 35 modifications introduced by suppression, insertion and/or substitution of at least one nucleotide coding for a protein having the same biological activity as the transcription factor CATfIIIA.

09374304 0 3 11

- 10) DNA sequence according to ~~one of claims 5 to 9~~ as well as the DNA sequences which have a nucleotide sequence homology of at least 50 % or at least 60 % and preferably at least 70 % with the said DNA sequence.
- 5 11) DNA sequence according to ~~one of claims 5 to 10~~ as well as the DNA sequences which code for a protein with a similar function the AA sequence of which has a homology of at least 40 % and in particular 45 % or at least 50 %, rather at least 60 % and preferably at least 70 % with the AA sequence coded
10 by the said DNA sequence.
- 12) Polypeptide having the transcription factor function CATFIIIA and having the amino acid sequence SEQ ID N°3 coded by the DNA sequence according to ~~one of claims 5 to 11~~ and the analogues of this polypeptide.
- 15 13) Process for the preparation of the recombinant protein CATFIIII having the amino acid sequence SEQ ID N°3 comprising expression of the DNA sequence according to ~~one of claims 5 to 11~~ in an appropriate host then isolation and purification of the said recombinant protein.
- 20 14) Expression vector containing the DNA sequence according to ~~one of claims 5 to 11~~.
- 15) Host cell transformed with a vector according to claim 14.
- 16) Process as defined in claim 13 in which the host cell is
25 DH5 alpha E. coli or XL1-Blue E. coli.
- 17) Process as defined in claim 13 in which the host cell is Saccharomyces cerevisiae.
- 18) Plasmid deposited at the CNCM under the number I-2072.
- 19) Process of screening antifungal products characterized in
30 that it comprises a stage where the the transcription activity factor of CATFIIIA as defined in claim 12 is measured in the presence of each of the products the antifungal properties of which need to be determined and the products having an inhibitory effect on this activity are
35 selected.
- 20) Use of a product selected by the process according to claim 19 in order to obtain an antifungal agent.
- 21) Use of the gene of the transcription factor CATfIIIA of

Candida albicans or of the transcription factor coded by this gene according to one of claims 5 to 12 for the selection of a product with antifungal properties according to claim 19 as an inhibitor of the transcription factor of Candida albicans.

- 5 22) Pharmaceutical compositions containing as active ingredient at least one inhibitor of the transcription factor of Candida albicans as defined in claim 21.
- 23) Use of compositions as defined in claim 22 as antifungal agents.
- 10 24) Method of inducing an immunological response in a mammal comprising the inoculation of this mammal with the polypeptide as defined in claim 12 or a fragment of this polypeptide having the same function in order to produce an antibody making it possible to protect the animal against the
- 15 disease.
- 25) Antibody directed against the polypeptide as defined in claim 12 or a fragment of this polypeptide having the same function.
- 26) Use of the CATfIIIA gene or of the transcription factor
- 20 coded by this gene according to ~~one of claims 5 to 12~~ for the preparation of compositions which can be used for the diagnosis or the treatment of diseases caused by the pathogenic yeast Candida albicans.
- 27) Kit for the diagnosis of fungal infections comprising a
- 25 DNA sequence as defined in ~~one of claims 5 to 11~~ or a sequence having a similar function or a functional fragment of this sequence, the polypeptide coded by this sequence or a polypeptide fragment having the same function or an antibody directed against such a polypeptide coded by this DNA
- 30 sequence or against a fragment of this polypeptide.

Candida albicans tfIIIA gene (CatfIIIA) and the coded
CATfIIIA protein.

The present invention relates to the Candida albicans
5 transcription factor hereafter called CATfIIIA and its
analogues as well as the polynucleotides (RNA, DNA) coding
for this protein or for the polypeptide analogues of this
protein.

The present invention also relates to the preparation
10 process for these polypeptides and polynucleotides, their use
for the study of the transcription mechanisms in Candida
albicans and for the preparation of inhibitors of this
transcription factor CATfIIIA which can be used as an
antifungal agent, and the pharmaceutical compositions
15 containing such inhibitors.

Therefore the present invention in particular relates to
a new transcription factor of Candida albicans and the DNA
sequence coding for this transcription factor, their
preparation and their uses.

20 We will also use hereafter the following abbreviations:
AA for amino acids, NA for nucleic acids, RNA for ribonucleic
acid, RNase for ribonuclease, DNA or dDNA for deoxyribonucleic
acid, cDNA for complementary DNA, bp for base pairs, PCR for
polymerase chain reaction, CA or Candida a. for Candida
25 albicans and SC or Saccharomyces c. for Saccharomyces
cerevisiae.

The term screening which designates a specific screening
technique and the term primer which designates an
oligonucleotide used as a primer will also be used.

30 The term polynucleotide hereafter designates the
polynucleotides of the present invention i.e. the DNA
sequences and also the RNA sequences coding for the CATfIIIA
factor of the present invention and its homologues having the
same transcription factor function. The term CatfIII has the
35 meaning given above for polynucleotides.

The term polypeptides designates hereafter the
polypeptides of the present invention i.e. the CATfIIIA
factor of the present invention and its functional analogues

or homologues as defined hereafter, thus having the same transcription factor function. The term CATFIIIA has the meaning given to polypeptides above.

We will call the gene coding for the transcription factor TFIIIA tfIIIA (or tfC2) while CATfIIIA (or CATfC2) designates the gene coding for the transcription factor CATFIIIA of *Candida albicans*.

The range of known fungal infections extends from fungal attack of the skin or nails to more serious mycotic infections of internal organs. Such infections and the diseases which result from them, such as mycosis are identified. Antimycotic substances with fungistatic or fungicidal effects are used for the treatment of these mycoses.

The present invention thus relates to the identification of antimycotic substances and in particular anti-*Candida albicans* substances.

The present invention thus relates to inhibitors of transcription factors which can be used as antifungal agents. *Candida albicans* is a pathogenic yeast which causes infectious diseases in the human body. With the aim of finding of a means of treating diseases, intracellular targets can be chosen and the transcription factor TFIIIA can be one of these targets.

In eucaryotic organisms, this factor plays a key role in the initiation of transcription of 5S RNA genes by RNA-polymerase III. In particular for SC which is a similar yeast to CA, it has been shown that this SC yeast could not survive without an additional source of 5S RNA when the chromosomal gene of factor TFIIIA was interrupted, this additional 5S RNA being synthesized using a plasmid without the participation of factor TFIIIA (reference: S. Camier, A.-M. Dechampesme, A. Sentenac./Proc. Natl. Acad. Sci. (1995) 92, 9338-9342).

The tfIIInd gene and the corresponding TFIIIA protein are involved in regulation of the biological transcription mechanism as indicated below.

Since the TFIII protein was purified as transcription factor for the first time in 1980 from *Xenopus* oocytes

[Segall and al. Biol. Chem., 255, 11986-11991 (1980)], work has been carried out in vivo and in vitro in the *Xenopus* in order to study the transcription control mechanism exercised by TFIIIA. It has thus been shown that *Xenopus* TFIIIA is
 5 necessary for the initiation of transcription of the 5S RNA gene [Sakonji and al, Cell 19, 13-25 (1980)] and binds to an internal control region of the 5S RNA gene [Bogenhagen and al, Cell, 19, 27-35 (1980)].

The nucleotide sequence of the cDNA of *Xenopus* TfIIIA
 10 and the corresponding amino acid sequence have already been published [Ginberg et al, Cell, 39, 479-489 (1984)]. It can be noted that this gene codes for a protein having 9 zinc fingers, a zinc finger corresponding to a moiety containing two cysteines and two histidines linked by a zinc atom (CYS2
 15 HIS2) (C2H2). This zinc finger structure constitutes a linking domain of proteins to the DNA and is therefore considered as an essential domain for a group of proteins which bind to DNA (DNA binding proteins). [Miller et al, Embo J., 4, 1607-1614 (1985)]

20 It can be noted that other transcription factors binding to DNA which also have this zinc finger structure are known such as for example, in human beings, XT1 of the Wilms human tumor gene, [Gessier et al, Nature, 343, 774-778 (1990)], the human transcription repressor YY1 [Shi et al, Cell, 67, 377-
 25 388 (1991)], the MAZ protein combined with the promoter cMYC [Bossone et al, Proc. Natl. Acad. Sci., USA, 89, 7452-7456 (1992)] or also sp1 [Kuwahara et al, J. Biol. Chem, 269, 8627-8631 (1990)].

The study of different organisms such as human beings in
 30 particular, the *Xenopus* or *Candida albicans* has shown that what can be called a family of TFIIIA transcription factors exist which have the following characteristics:

- they are combined with RNA polymerase III
- they have 9 zinc fingers
- 35 - they are indispensable for the transcription of the gene coding for 5S RNA.

A known essential function of the protein coded by the tfIIIA gene (tfC2) in yeast is to initiate the transcription

of the 5S RNA gene in *Saccharomyces cerevisiae* (Camier et al., Proc. Natl. Acad. Sci USA (1995) 92: 9338-9342).

The present invention has thus made it possible to isolate the DNA and RNA polynucleotides coding for the protein of the transcription factor CATFIIIA of *Candida albicans* and to reveal their nucleotide sequences.

A subject of the present invention is therefore an isolated polynucleotide containing a nucleotide sequence chosen from the following group:

- 10 a) a polynucleotide having at least 50 % or at least 60 % and preferably at least 70 % identity with a polynucleotide coding for a polypeptide having the transcription factor function and having an amino acid sequence homologous with the sequence SEQ ID N°3 indicated hereafter.
- 15 b) a complementary polynucleotide of polynucleotide a)
- c) a polynucleotide comprising at least 15 consecutive bases of the polynucleotide defined in a) and b).

A subject of the present invention is therefore a polynucleotide defined above in that this polynucleotide is a DNA.

A subject of the present invention is therefore a polynucleotide defined above in that this polynucleotide is an RNA.

A more precise subject of the present invention is the polynucleotide as defined above comprising the nucleotide sequence SEQ ID N°1.

The present invention has thus made it possible to isolate the DNA sequence coding for the transcription factor CATFIIIA of *Candida albicans*.

The present invention has also made it possible to reveal the nucleic acid sequence of the CATfIIIA gene and also the amino acid sequence of the CATFIIIA protein coded by this gene.

A subject of the present invention is therefore a DNA sequence as defined by the polynucleotide above, characterized in that this DNA sequence is that of the CATfIIIA gene coding for a protein having the biological function of transcription factor CATFIIIA of *Candida albicans*

and containing the nucleotide sequence SEQ ID N°1.

Such a SEQ ID n°1 sequence of the present invention therefore comprises 2060 nucleotides.

A precise subject of the present invention is a DNA
5 sequence as defined above having the sequence starting at nucleotide 720 and finishing at nucleotide 1955 of SEQ ID N°1.

Such a sequence thus comprises 1236 nucleotides.

A subject of the present invention is also the DNA
10 sequence of the CATfIIIA gene as defined above coding for the amino acid sequence SEQ ID N°3.

The sequence SEQ ID N°3 thus comprises 412 AA.

A particular subject of the present invention is the DNA
15 sequence coding for the transcription factor CATFIII as defined above as well as the DNA sequences which hybridize with it and/or have a significant homology with this sequence or of the fragments of it and having the same function.

A subject of the present invention is also a DNA
20 sequence as defined above, comprising modifications introduced by suppression, insertion and/or substitution of at least one nucleotide coding for a protein with the same biological activity as the transcription factor CATFIIIA.

A particular subject of the present invention is the DNA
25 sequence as defined above as well as DNA sequences which have a nucleotide sequence homology of at least 50 % or at least 60 % and preferably at least 70 % with the said DNA sequence.

Therefore a subject of the present invention is also the
DNA sequence as defined above as well as the DNA sequences which code for a protein of similar function, the AA sequence
30 of which has a homology of at least 40 % and in particular 45 % or of at least 50 %, rather at least 60 % and preferably at least 70 % with the AA sequence coded by the said DNA sequence.

By sequences which hybridize, are included the DNA sequences
35 which hybridize with one of the DNA sequences above under standard conditions of high, medium or low stringency and which code for a polypeptide having the same transcription factor function. The stringency conditions are those carried

out under the conditions known to a person skilled in the art such as those described by Sambrook et al, Molecular cloning, Cold Spring Harbor Laboratory Press, 1989. Such stringency conditions are for example hybridization at 65°C, for 18
 5 hours in a 5 x SSPE; 10 x Denhardt's; 100 µg/ml ssDNA; 1 % SDS solution followed by washing 3 times for 5 minutes with 2 x SSC; 0.05 % SDS, then washing 3 times for 15 minutes at 65°C in 1 x SSC; 0.1 % SDS. High stringency conditions include for example hybridization at 65°C for 18 hours in a 5
 10 x SSPE; 10 x Denhardt; 100 µg/ml ssDNA; 1 % SDS solution followed by washing twice for 20 minutes with a 2 x SSC; 0.05 % SDS solution at 65°C, followed by a final washing for 45 minutes in a 0.1 x SSC; 0.1 % SDS solution at 65°C. Medium stringency conditions include for example a final washing for
 15 20 minutes in a 0.2 x SSC, 0.1 % SDS solution at 65°C.

By sequences which have a significant homology, are included sequences with a moderate or high nucleotide sequence similarity with one of the DNA sequences above and which code for a protein having the same transcription factor
 20 function.

By similar DNA sequence, is therefore meant DNA sequences which can belong to mycetes other than *Candida albicans* and in particular to SC, and which are similar or identical to the DNA sequence of the *Candida albicans*
 25 *CatfIIIA* gene. These similar DNA sequences are not necessarily identical to the DNA sequence of the *Candida albicans CatfIIIA* gene. The sequence homology at nucleotide level can be moderate or high. The present invention thus relates in particular to DNA sequences which have a
 30 nucleotide sequence homology of at least 50 %, preferably at least 60 % and even more preferably at least 70 % with the *CATfIIIA* sequence of the present invention.

In addition, these similar DNA sequences do not necessarily code for identical proteins, at the amino acid sequence
 35 level, to the protein coded by the *CATfIIIA* gene. The present invention therefore relates in particular to DNA sequences which code for proteins said to be homologous, having an amino acid sequence homology of at least 40 %, in

particular 45 %, preferably at least of 50 %, more preferably at least of 60 % and even more preferably at least of 70 % with the protein coded by CATfIIIA of the present invention.

The gene of the present invention is represented as a
 5 single strand DNA sequence as indicated in SEQ ID N°1 but it is understood that the present invention includes the complementary DNA sequence of this single strand DNA sequence and also includes the DNA sequence said to be double stranded constituted by these two DNA sequences complementary to each
 10 other.

The DNA sequence as defined above is an example of a combination of codons coding for the amino acids corresponding to the amino acid sequence SEQ ID N°3, but it is also understood that the present invention includes any
 15 other arbitrary combination of codons coding for this same amino acid sequence SEQ ID N°3.

For the preparation of polynucleotides and in particular DNA sequences as defined above, modified DNA sequences as indicated above or also homologous DNA sequences as defined
 20 above, techniques known to a person skilled in the art and in particular those described in the book by Sambrook, J. Fritsh, E. F. & Maniatis, T. (1989) entitled: 'Molecular cloning: a laboratory manual, Laboratory, Cold Spring Harbor NY can be used.

25 The homologous DNA sequences as defined above can in particular be isolated according to the methods known to a person skilled in the art for example by PCR technique using degenerated nucleotide primers to amplify these DNA from gene banks or cDNA banks of the corresponding mycetes. The cDNA
 30 can also be prepared from mRNA isolated from mycetes of different species studied within the scope of the present invention such as *Candida albicans* but also for example: *Candida stellatoidea*, *Candida tropicalis*, *Candida parapsilosis*, *Candida krusei*, *Candida pseudotropicalis*,
 35 *Candida quilliermondii*, *Candida glabrata*, *Candida lusitanae* or *Candida rugosa* or also mycetes such as *Saccharomyces cerevisiae* or also *Aspergillus* or *Cryptococcus* and in particular, for example, *Aspergillus fumigatus*, *Coccidioides*

immitis, *Cryptococcus neoformans*, *Histoplasma capsulatum*,
Blastomyces dermatitidis, *Paracoccidioides brasiliensis* and
Sporothrix schenckii type mycetes or also mycetes of the
 classes of phycomycetes or eumycetes, in particular the sub-
 5 classes of basidiomycetes, ascomycetes, mehiacomycetales
 (yeast) and plectascales, gymnascales (skin and hair fungi)
 or of the hyphomycetes class, in particular the
 conidiosporales and thallosporales sub-classes amongst which
 are the following species: mucor, rhizopus, coccidioides,
 10 paracoccidioides (*blastomyces brasiliensis*), endomyces
 (*blastomyces*), aspergillus, menicilium (*scopulariopsis*),
 trichophyton (*ctenomyces*), epidermophyton, microsporon,
 piedraia, hormodendron, phialophora, sporotrichon,
 cryptococcus, candida, geotrichum, trichosporon or also
 15 toropsulosis.

The polynucleotides of the present invention can thus be
 obtained by using the usual cloning and screening methods
 such as those of cloning and sequencing from fragments of
 chromosomal DNA extracted from cells. For example, in order
 20 to obtain the polynucleotides of the present invention, a
 bank of chromosomal DNA fragments can be used. A probe
 corresponding to an oligonucleotide labelled with a
 radioactive element, preferably constituted by 17 or more
 nucleotides and derived from a partial sequence can be
 25 prepared. The clones containing DNA identical to that of the
 probe can be thus identified under stringent conditions. By
 the sequencing of the thus identified individual clones,
 using the sequencing primers originating from the original
 sequence, it is then possible to extend the sequence in both
 30 directions in order to determine the complete gene sequence.
 In a usual and efficient fashion, such sequencing can be
 carried out by using denatured double strand DNA prepared
 from a plasmid. Such techniques are described by Maniatis,
 T. Fritsch, E.F. and Sambrook as indicated
 35 above. (Laboratory Manual, Cold Spring Harbor, New York (1989)
 (in particular in 1.90 and 13.70 in the chapters of screening
 by hybridization and sequencing from denatured double strand
 DNA).

Within the scope of the present invention, a bank of chromosomal DNA fragments of *Candida albicans* can in particular be used as indicated hereafter in Example 1 in the experimental part.

5 A detailed description of the operating conditions in which the present invention has been carried out is given below.

A very particular subject of the present invention is the polypeptide having the transcription factor function
10 CATFIIIA and having the amino acid sequence SEQ ID N°3 coded by the DNA sequence as defined above and the analogues of this polypeptide.

By polypeptide analogues, are understood polypeptides, the amino acid sequence of which has been modified by
15 substitution, suppression or addition of one or more amino acids but which retain the same biological function. Such polypeptide analogues can be produced spontaneously or can be produced by post-transcriptional modification or also by modification of the DNA sequence of the present invention as
20 indicated above, using techniques known to a person skilled in the art: Amongst these techniques, the technique of directed mutagenesis known to a person skilled in the art (Kramer, W., et al., Nucl. Acids Res., 12, 9441 (1984); Kramer, W. and Fritz, H.J., Methods in Enzymology, 154, 350
25 (1987); Zoller, M.J. and Smith, M. Methods in Enzymology, 100, 468 (1983)) can in particular be mentioned.

Modified DNA synthesis can be carried out as indicated above and in particular by using well known chemical synthesis techniques such as for example the phosphotriester method
30 [Letsinger, R.L and Ogilvie, K.K., K. Am. CHEM. Soc., 91, 3350 (1969); Merrifield, R.B., Sciences, 150, 178 (1968)] or the phosphoamidite method [Beaucage, S.L and Caruthers, M.H., Tetrahedron Lett., 22, 1859 (1981); McBRIDE, L.J. and Caruthers, M.H. Tetrahedron Lett., 24 245 (1983)] or also
35 the combination of these methods.

The polypeptides of the present invention can therefore be prepared using techniques known to a person skilled in the art, in particular partially by chemical synthesis or also by

the recombinant DNA technique by expression in a procaryotic or eucaryotic host cell as indicated hereafter.

A particular subject of the present invention is the process for the preparation of the recombinant protein

5 CATFIIIA having the amino acid sequence SEQ ID N°3 comprising the expression of the DNA sequence as defined above in an appropriate host then isolation and purification of the said recombinant protein.

To produce the polypeptide of the present invention,
10 recombinant DNA techniques using genetic engineering and cell culture methods known to a person skilled in the art can in particular be used. The following stages can then be carried out: firstly preparation of the appropriate gene, then incorporation of this gene into a vector, transfer of the
15 carrier vector of the gene into an appropriate host cell, production of the polypeptide by expression of the gene, isolation of the polypeptide, the polypeptide thus produced can then be purified.

The polypeptides of the present invention obtained by
20 expression of the polynucleotides of the present invention can be purified from cell cultures transformed by methods well known to a person skilled in the art such as precipitation with the ammonium sulphate or ethanol, extraction under acid conditions, anion or cation exchange
25 chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and high performance liquid chromatography (HPLC). Techniques well known to a person skilled in the art can be used to regenerate the protein when it is denatured during its
30 isolation or purification.

The DNA sequences according to the present invention and in particular SEQ ID N°1 and SEQ ID N°2 can be prepared according to techniques known to a person skilled in the art in particular by chemical synthesis or by screening of a gene
35 bank or a cDNA bank using synthetic oligonucleotide probes by known hybridization techniques, thus amplification of DNA from isolated fragments or also by reverse transcriptase from messenger RNA (mRNA).

The advantage of the technique comprising firstly the isolation of mRNA by extraction of the total RNA then the synthesis of cDNA from these mRNA by reverse transcriptase in particular rests on the fact that the mRNA do not contain
 5 introns even though these non-coding sequences are presented in the genomic DNA.

The usual cloning techniques known to a person skilled in the art and in particular described in the book by Sambrook, J. Fritsh, E. F. S Maniatis, T. (1989) entitled:
 10 'Molecular cloning: a laboratory manual, Laboratory, Cold Spring Harbor NY can then be carried out.
 In these techniques, cloning can be carried out by insertion of a fragment into a plasmid which can be provided with a suitable commercial kit then transformation of a bacterial
 15 strain by the plasmid thus obtained. In particular the XL1 Blue or DH5 alpha E. coli strain can be used. The clones can then be cultured in order to extract the plasmid DNA according to standard techniques known to a person skilled in the art referred to above (Sambrook, Fritsh and Maniatis).
 20 The DNA sequencing of the amplified fragment contained in the plasmid DNA can then be carried out.

The polypeptides of the present invention can be obtained by expression in a host cell containing a polynucleotide according to the present invention and in
 25 particular a DNA sequence coding for a polypeptide of the present invention preceded by a suitable promoter sequence. The host cell can be a procaryotic cell, for example E. coli or a eucaryotic cell such as yeast such as for example ascomycetes amongst which is saccharomyces or also mammalian
 30 cells such as Cos cells for example.

A particular subject of the present invention is the expression vector containing a DNA sequence as defined above. In the expression vector, such a DNA sequence is therefore in particular the DNA sequence of the CATfIIIA gene coding for a
 35 protein with the biological function of the transcription factor CATfIIIA of Candida albicans containing the nucleotide sequence SEQ ID N°1.

In the expression vector, such a DNA sequence is thus more

particularly the DNA sequence starting with nucleotide 720 and finishing at nucleotide 1955 of SEQ ID N°1.

In the expression vector, such a DNA sequence is thus also more particularly that of the CATFIIIA gene as defined above

5 coding for the amino acid sequence SEQ ID N°3.

In the expression vector, such a DNA sequence is thus a DNA sequence as defined above coding for the transcription factor CATFIIIA as well as the DNA sequences which hybridize with it and/or have a significant homology with this sequence or

10 fragments of it, or also DNA sequences comprising modifications introduced by suppression, insertion and/or substitution of at least one nucleotide coding for a protein having the same biological activity as the transcription factor CATFIIIA.

15 In the expression vector, such a DNA sequence is in particular a DNA sequence as defined above as well as similar DNA sequences which have a nucleotide sequence homology of at least 50 % or at least 60 % and preferably at least 70 % with the said DNA sequence or also similar DNA sequences which
20 code for a protein, the AA sequence of which has a homology of at least 40 % and in particular of 45 % or of at least 50 %, rather at least 60 % and preferably at least 70 % with the AA sequence coded by the said DNA sequence.

The expression vectors are vectors allowing the expression of
25 the protein under the control of a suitable promoter. Such a vector can be a plasmid, a cosmid or viral DNA. For the procaryotic cells, the promoter can for example be the lac promoter, the trp promoter, the tac promoter, the β -lactamase promoter or the PL promoter. For the yeast cells, the
30 promoter can be for example the PGK promoter or the GAL promoter. For mammalian cells, the promoter can for example be the SV40 promoter or adenovirus promoters.

Baculovirus type vectors can be also used for the expression in insect cells.

35 The host cells are for example procaryotic cells or eucaryotic cells. The procaryotic cells are for example E. coli, Bacillus or Streptomyces. The eucaryotic host cells include yeasts as well as of the cells of higher organisms,

05833804-072204

for example mammalian cells or insect cells. The mammalian cells are for example fibroblasts such as hamster CHO or BHK cells and monkey Cos cells. The insect cells are for example SF9 cells.

5 The present invention therefore relates to a process which comprises the expression of a polynucleotide according to the present invention coding for the CATFIIIA protein in a host cell transformed by a polynucleotide according to the present invention and in particular a DNA sequence coding for
10 the amino acid sequence SEQ ID N°3. In the implementation of such a process, the host cell is in particular a eucaryotic cell.

For the implementation of the present invention, the vectors used can for example be pGEX or pBAD and the host cell can be
15 E. coli or for example the vector pYX222 and the host cell can be in particular *Saccharomyces cerevisiae*.

A particular subject of the present invention is the host cell transformed with a vector as defined above and containing a DNA sequence according to the present invention.

20 A subject of the present invention is therefore the process for the preparation of a recombinant protein according to the present invention, as defined above, in which the host cell is DH5 alpha E. coli or XL1-Blue E. coli or in particular *Saccharomyces cerevisiae*.

25 A detailed account of the conditions under which the operations indicated above can be carried out is given¹ hereafter in the experimental part. A plasmid is thus obtained in which the gene of the present invention is inserted and this plasmid introduced into a host cell is then
30 obtained by operating according to the usual techniques known to a person skilled in the art.

A very precise subject of the present invention is the plasmid deposited at the CNCM under the number I-2072.

It therefore particularly relates to the XL1-Blue/Yep24-
35 Catfc2 strain containing the CATfIIIA gene according to the present invention.

This gene corresponds therefore to the sequence 720-1955 of SEQ ID N°1.

The operating conditions under which the present invention was carried out are described hereafter in the experimental part.

The TFIIIA protein coded by the CATfIIIA gene is therefore a transcription factor. In fact, the TFIIIA protein coded by the gene of the present invention has a biological role as a protein binding to the DNA and would be useful as transcription factor.

In particular, the gene of the present invention is expressed in different tissues and plays an important role in the initiation of the transcription of the 5s ribosomal RNA gene. The study of these factors can also be useful in the analysis of transcription regulation mechanisms.

A subject of the present invention is therefore a process for screening antifungal products characterized in that it comprises a stage where the activity of transcription factor CATfIIIA as defined above is measured in the presence of each of the products whose antifungal properties need to be determined and the products with an inhibitory effect on this activity are selected.

The demonstration within the scope of the present invention of the functional homology of the transcription factors of *Candida albicans* and *Saccharomyces cerevisiae*, illustrated in the experimental part hereafter, make it possible to envisage numerous applications for the transcription factor CATfIIIA of the present invention.

In particular because of the fact that it appears that the activity of SCTfIIIA is essential for cell survival, substances which inhibit this activity can be used as antifungal agents, either as medicaments or at an industrial level.

For example, to screen antifungal substances such as substances active on *Candida albicans*, the activity of CATfIIIA or one of its functional homologues constituted by a TFIIIA transcription factor is measured in the presence of each of the products whose antifungal properties need to be determined and the products having an inhibitory effect on this activity are selected.

Such screening can be carried out by measuring the transcription activity of TFIIIA in the presence of activators or of potential inhibitors to be tested. The transcription of 5S RNA can for example be measured in vitro
5 directly by detecting the synthesis of the 5S RNA in an appropriate reaction medium.

The transcription activity can also be measured in vivo by a cell viability test. For example, transcription activity can be favourably measured in mutant *Saccharomyces cerevisiae*
10 cells not expressing SC TFIIIA transformed by the CATfIIIA gene.

The invention also encompasses the use of a product selected as indicated above for its properties of inhibiting a TFIIIA transcription factor in order to obtain of an
15 antifungal agent.

The present invention will be better understood by reference to the experimental part which follows and which describes the cloning of the CATfIIIA gene of the present invention.

20 A subject of the present invention is thus the use of a product selected by the process of screening antifungal products as defined above in order to obtain an antifungal agent.

A subject of the present invention is also the use of
25 the transcription factor CATfIIIA gene of *Candida albicans* or the transcription factor coded by this gene as defined above for the selection of a product having antifungal properties as defined above and used as inhibitor of the transcription factor of *Candida albicans*.

30 A subject of the present invention is also pharmaceutical compositions containing at least one inhibitor of the transcription factor of *Candida albicans* as defined above as active ingredient.

Such compositions can in particular be useful for treating
35 topical and systemic fungal infections.

The pharmaceutical compositions indicated above can be administered by oral, rectal, parenteral route or by local route as a topical application on the skin and mucous

membranes or by injection, by intravenous or intramuscular route. These compositions can be solid or liquid and be presented in all the pharmaceutical forms currently used in human medicine such as, for example, plain or sugar coated
5 tablets, gelatin capsules, granules, suppositories, injectable preparations, ointments, creams, gels and aerosol preparations; they are prepared according to usual methods. The active ingredient can be incorporated in excipients normally used in these pharmaceutical compositions, such as
10 talc, gum arabic, lactose, starch, magnesium stearate, the cocoa butter, aqueous or non aqueous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various wetting, dispersing or emulsifying agents, and preservatives.

15 The dose will be variable according to the product used, the subject treated and the disease in question.

A particular subject of the present invention is thus the use of compositions as defined above such as antifungal agents.

20 A subject of the present invention is also a method of inducing an immunological response in a mammal comprising the inoculation of this mammal with the polypeptide according to the present invention as defined above or a fragment of this polypeptide having the same function in order to produce an
25 antibody protecting the animal against the disease.

A subject of the present invention is therefore
antibodies directed against the polypeptides of the present invention as defined above having the transcription factor function CATFIIIA or against a fragment of these polypeptides
30 having the same function and coded by the polynucleotides of the present invention and in particular by a DNA sequence as defined above.

The polypeptides of the present invention can thus be used as immunogens to produce immunospecific antibodies of these
35 polypeptides. The term antibody designates antibodies which can equally be monoclonal, polyclonal, chimeric, single chain, non-human antibodies and human antibodies, as well as Fab fragments, including the products of a Fab immunoglobulin

bank. The antibodies produced against the polypeptides of the present invention can be obtained by administration of the polypeptides of the present invention or fragments carrying epitopes, their analogues or also animal cells, preferably non-human, by using routine protocols for the preparation of monoclonal antibodies. Such antibodies can be prepared by methods well known in this field such as those described in the book Antibodies, Laboratory manual Ed. Harbow and David Larre, Cold Spring Harbor laboratory Eds, 1988.

A very particular subject of the present invention is thus an antibody directed against the CATFIIIA protein of the present invention or a fragment of this protein in particular having the same function.

A subject of the present invention is also the use of the CATfIIIA transcription factor gene or the transcription factor coded by this gene as defined above for the preparation of compositions which can be used for the diagnosis or treatment of diseases caused by the pathogenic yeast *Candida albicans*.

The present invention also relates to the use of the polynucleotides of the present invention as diagnostic reagents. The detection of a polynucleotide according to the present invention coding for the TFIIIA protein of *Candida albicans* or of its analogues in a eucaryotic cell in particular a mammalian cell and more particularly a human being, can constitute a means of diagnosing a disease: thus, such a polynucleotide according to the present invention and in particular a DNA sequence can be detected by a wide variety of techniques in a eucaryotic cell in particular a mammal and more particularly a human being, infected by an organism containing at least one of the polynucleotides of the present invention. The nucleic acids for such a use as a diagnostic tool can be detected in infected cells or tissues, such as bone, blood, muscle, cartilage or skin. For this detection, the genomic DNA can be used directly or also be amplified by PCR or another amplification technique. The RNA or DNA and cDNA can also be used with the same purpose. By

amplification techniques, the line of the mycete present in a eucaryote in particular a mammal and more particularly a human being, can be characterized by analysis of the genotype. Deletions or insertions can be detected by a change in the size of the amplified product in comparison with the genotype of the reference sequence. The points of mutation can be identified by hybridization of the DNA amplified with the sequences, labelled by a radioactive element, of polynucleotides of the present invention. Perfectly complementary sequences can therefore be distinguished from the duplex which poorly resist digestion by nucleases. The DNA sequence differences can also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agent, or by direct DNA sequencing (reference: Myers et al. Science, 230: 1242 (1985)). Sequence changes at specific locations can also be revealed by protection experiments against nucleases such as RNase I and S1 or by chemical cleavage methods (reference: Cotton et al., Proc Natl Acad Sci, USA, 85: 4397-4401 (1985)).

Cells containing one of the polynucleotides of the present invention carrying mutations or polymorphisms can also be detected by a large number of techniques making it possible in particular to determine the serotype. For example, the RT-PCR technique can be used to detect the mutations. It is particularly preferable to use RT-PCR techniques in conjunction with automatic detection systems, such as for example the GeneScan technique. RNA and cDNA can be used in the PCR or RT-PCR techniques. For example, complementary primers of polynucleotides coding for the polypeptides of the present invention can be used to identify and analyse the mutations.

Primers can therefore be used to amplify an isolated DNA from the infected individual. In this way mutations in the DNA sequence can be detected and used to diagnose the infection and determine the serotype or the classification of the infectious agent. Such techniques are standard for a person skilled in the art and are described in particular in the manual 'Current Protocols in Molecular Biology', Ausubel et

al, ed. John Wiley & sons, Inc., 1995).

The present invention therefore relates to a process of diagnosing a disease and preferably a fungal infection caused in particular by *Candida albicans* such as mycoses as

5 indicated above, this process comprising the determination from a sample taken from an infected individual, an increase in the quantity of polynucleotide of the present invention. Such a polynucleotide can in particular have a DNA sequence of the present invention as defined above.

10 Increases or reductions in the quantity of polynucleotides can be measured by techniques well known to a person skilled in the art such as in particular amplification, PCR, RT PCR, Northern blotting or other hybridization techniques.

In addition, a diagnosis method in accordance with the
15 present invention consists of the detection of too large an expression of polypeptides of the present invention, in comparison with control samples constituted by normal, non-infected tissues used to detect the presence of an infection. The techniques which can therefore be used to detect the
20 quantities of proteins expressed in a host cell sample are well known to a person skilled in the art. For example the radioimmunoassay or competitive-binding techniques, Western Blot analysis and ELISA test (ref Ausubel indicated above) can thus be mentioned.

25 A subject of the present invention is also a kit for the diagnosis of fungal infections comprising a DNA sequence according to the present invention as defined above or a sequence having a similar function or a functional fragment of this sequence, the polypeptide coded by this sequence or a
30 polypeptide fragment having the same function or an antibody directed against such a polypeptide coded by this DNA sequence or against a fragment of this polypeptide.

This kit can thus contain a DNA sequence according to the present invention as defined above and for example the DNA
35 sequence SEQ ID N°1 or a fragment of this sequence or also the sequence 720 to 1955 of SEQ ID N°1.

Such kit could also contain a polypeptide according to the present invention or a fragment of this polypeptide and in

particular the protein having the AA sequence SEQ ID N°3 or also an antibody as defined above.

Such a kit can be prepared according to methods well known to a person skilled in the art.

- 5 The sequences SEQ ID N° 1 to 9 indicated in the present invention are described hereafter.

The experimental part hereafter makes it possible to describe the present invention without however limiting it.

Experimental part

- 10 **Example 1**: Cloning and sequencing of the CATfIIIA gene

a) Culture Conditions:

The bacteria *Escherichia coli* (*E. coli*) of the DH5 alpha (Gibco BRL) or XL1- Blue type K12 (Stratagene) line was used for the preparation of the plasmids of the present invention.

- 15 The growth of this bacteria was carried out according to usual conditions in liquid LB medium which contains 10 g of bactotryptone, 5 g of yeast extract and 10 g of NaCl per litre of water and which also contains 100 micro g/ml of ampicillin (SIGMA).

- 20 The colony was removed onto solid LB + agar + ampicillin medium then cultivated in 100 ml of LB medium and incubated to OD (600 nm) = 0.8.

The incubation was carried out at 37°C under a normal atmosphere and agitation at 225 rpm.

- 25 The viability of the strain is verified when the strain grows on LB + ampicillin medium at 100 micro g/ml.

It can be noted that a gene resistant to the Bla ampicillin forms part of the vector in which the fragments of CATfIIIA are cloned. Therefore, the selection of strains containing

- 30 the plasmids containing the tfIIIA gene of *Candida albicans* of the present invention can be carried out by culture of the strains in this medium containing ampicillin (100 micro g/ml), such a medium only allowing the survival of strains which contain the gene resistant to the ampicillin and
35 therefore only strains which contain the tfIIIA gene of *Candida a.* of the present invention.

For the preservation of the strains obtained, 15 % of glycerol is added to the culture medium: the cultures are

therefore preserved in the suspension medium LB +100 micrograms/ml of ampicillin + 15 % of glycerol at the bacterial concentration of OD (600 nm = 0.8 in the form of aliquots in cryotubes of 1 ml per tube.

- 5 For the sequencing, the plasmid DNA of several bacteria originating from each of the cloning operations indicated hereafter is prepared using a commercial kit (Qiagen Plasmids kit). The fragments corresponding to the sequence of the CATfIIIA gene are sequenced on the two strands according to
10 standard techniques known to a person skilled in the art (use of the ABI 377 XL sequencer, Perkin Elmer).

b) Cloning and sequencing of the CATfIIIA gene:

Within the scope of the present invention, the gene coding for the transcription factor CA i.e. SEQ ID N°1 represented in Figure 1 was isolated from the gene fragment bank of *Candida albicans*. (Sanglard et al., Antimicrobial agents and chemotherapy 39, 2378-2386, (1995)).

The structure of the gene was identified by sequencing.
The strategy used rests on the hypothesis that SC and CA are
20 similar yeasts the gene structure of which can be homologous.
The following process is then carried out:

Within the scope of the present invention, by using the Stanford internet site which makes it possible to access the preliminary sequences of the *Candida albicans* genome, a fraction of sequence homologous with *S. cerevisiae* tFI_{II}IA was identified. This fragment contains an open reading frame (258 bp) coding for a protein for which two zinc finger moieties and a region rich in serine residues characteristic of the TFI_{II}IA factor of SC can be identified. This open reading frame in reality contains 259 nucleotides. In order to amplify the fragment corresponding to *Candida albicans*, two oligonucleotides were selected from this sequence. These oligonucleotides are the following:

INT CAND located in the position 720-740 of SEQ ID N°1 and
35 called SEQ ID N°4 and

3' CAND located in the position 955-978 of SEQ ID N°1 and called SEQ ID N°5.

A fragment of 259 base pairs is thus obtained.

It was firstly confirmed by PCR that it is possible to amplify a fragment of CA genomic DNA, prepared from CA cells by the usual methods known to a person skilled in the art, and on the other hand in the CA gene bank. These

- 5 oligonucleotides have also made it possible to synthesize a fragment of DNA from genomic DNA of *Candida albicans* in order to prepare a probe labelled with ^{32}P (phosphorus 32) using a kit (Mega Prime, Amersham).

- This fragment was used for the screening of the bank of
10 genomic *Sau* 3A fragments of *Candida albicans* cloned in the *Bam*HI site of the vector YEp24 (multicopy-Ura3) [Botstein et al., *Gene*, 8, 17-24, (1979)].

- The DH5 alpha *E. coli* cells transformed with the vector YEp24 (multicopy vector with selection gene URA3) containing the
15 fragments described above (17000 clones) are plated on dishes containing a LB + ampicillin medium and cultured at 37°C.

- A replica on nitrocellulose filter is then treated by techniques known to a person skilled in the art such as for example NaOH: 0.5M, 5 minutes; Tris-HCl: 1M (pH = 7.5)
20 5 minutes; NaCl 1.5M/Tris-HCl 0.5M (pH 7.5).

- As regards drying, the filters are kept for 10 minutes at 80°C then fixed with UV (Stratalinker). Pre-hybridization and hybridization are carried out in a NaPO₄ buffer (pH 7.2) 0.5M; EDTA 10mM; SDS 7 % (ref., Church and Gilbert,
25 PNAS 81: 1991 (1984)).

- The probe is labelled with ^{32}P with the MegaPrime and (alpha ^{32}P) dCTP kit (Amersham UK). The hybridization is carried out overnight at 65°C. The filters are then washed in 1 % SDS, 40 mM NaPO₄ (pH 7.2), six times for 5 minutes at 65°C
30 and they are then subjected to autoradiography overnight. Hybridization on a filter with the probe labelled with ^{32}P has made it possible to select several positive clones which have been recultured in dishes in order to isolate them. Individual clones have thus been isolated.

- 35 Three types of clones are thus obtained which are called 9, 18 and 47 containing three different inserts of the CATfIIIA gene of the present invention: analysis by PCR confirmed the presence of the 259 bp fragment.

The YEp24 plasmids containing *Candida albicans* inserts were collected from these colonies. The restriction map of each of these plasmids was established and made it possible to note that all the inserts originate from the same region of the *Candida albicans* genome. For the sequencing of this region the following oligonucleotides were used:

INT-Cand located at position: 720-740 of SEQ ID N°1 and called SEQ ID N°4

3'-Cand located at position: 955-978 of SEQ ID N°1 and called SEQ ID N°5

Cont-Int located at position: 719-741 of SEQ ID N°1 and called SEQ ID N°6

Can-Kor1 located at position 1365-1389 of SEQ ID N°1 and called SEQ ID N°7

and the sequencer ABI 377 XL (Perkin Elmer). The sequencing of this region made it possible bring the following points to light:

- 1) The three clones all contain only one open reading frame, uninterrupted for 1236 bp with the same sequence which codes for a protein.
- 2) The open reading frame codes for a 412 AA protein which shows a significant homology with the TFIIIA factor of *Saccharomyces cerevisiae*. Analysis of the protein makes it possible to find the 9 zinc finger moieties which are characteristic of the transcription factor TFIIIA. Comparison of the proteinic sequences of SC CATFIIIA and TFIIIA, makes it possible to demonstrate a similarity of 50 % and an identity of 45 %. For the amino acid translation the fact that in *Candida albicans* the CTG codon is translated to serine and that there are 2 CTG codons in *Candida albicans* TFIIIA was taken into account.

The following should be noted:

- The preservation of the Serine rich region in the N-terminal part.
- the presence of a very long intermediate region between the 8 and 9 zinc fingers characteristic of SC.

The sequence differences between the TFIIIA proteins of SC and TFIIIA of *Candida albicans* is located in the C-terminal

part outside the zinc finger moieties.

The YEp24 plasmid containing the promoter region and the sequence coding for CATFIII was transformed in the XL1 Blue E. Coli strain then deposited under the number I-2072 at the
 5 CNM, Institut Pasteur 25 rue of Docteur ROUX 75015 Paris, on the 15th September 1998.

Example 2: expression of the tfIIIA gene

A fragment contained in clone 9 was amplified by PCR using primers containing sequences recognized by the restriction
 10 enzymes EcoRI and XhoI and hybridizing with the tfC2 gene, the primers are the following:

5-EcoTF located at position 720-732 of SEQ ID N°1 and called SEQ ID N°8 and

3'-XhoI located at position 1946-1960 of SEQ ID N°1 and
 15 called SEQ ID N°9.

Amplification by PCR of the genomic DNA is then carried out in the following manner:

0.5 micrograms of DNA of clone 9 is added to 50 microlitres of a reaction solution containing 200 nanograms/ml of each
 20 dNTP, the primers indicated above at a rate of 25 micromoles/l for each, 2mM MgCl₂, 1 x Pfu Buffer, 5U Pfu polymerase (Perkin Elmer).

The reaction medium is subjected to 30 PCR cycles each corresponding to 94°C for 30 seconds, then 60°C for 45
 25 seconds then 72°C for 1 minute.

The fragment containing the coding sequence for CATFIII was sub-cloned in the vectors pYX122 (CEN, HIS 3) and pYX222 (2 micron, HIS3) (R and D System). This plasmid was used to transform Saccharomyces c cells. YWRI (Mat alpha, can 1-100,
 30 his 3-11, leu 2-3, 112 trp 1-1, ura 3-1, ade 2-1, tfC2: leu2 + pJA230), (Camier and al, Proc. Natl. Acad. Sci. 92 9338-9342, 1995).

The strain transformed according to the same methods as those indicated above allows the expression of the transcription
 35 factor TFIIIA of Candida albicans containing a HA tag.

Conclusion

The experimental implementations indicated above therefore show the following points:

- 1) The TFIIIA factor gene of *Candida albicans* was isolated in three clones 9, 18 and 47 obtained as indicated above in Example 1 from the gene bank of *Candida albicans* using a hybridization technique. The structure of this gene was
5 identified by sequencing.
- 2) The CATFIIIA protein of the CATfIIIA gene obtained in Example 1 is constituted by 412 AA and shows a high homology with the SC TFIIIA factor. This protein contains a region rich in SER residues in the N-terminal and 9 zinc finger
10 part, the arrangement of which is identical to that of the TFIIIA protein of SC.
- 3) The sub-cloning of the gene of the TFIIIA factor of *Candida albicans* was carried out and the gene was placed under the control of an SC promoter.

CLAIMS

- 1) Isolated polynucleotide containing a nucleotide sequence chosen from the following group:
 - 5 a) a polynucleotide having at least 50 % or at least 60 % and preferably at least 70 % similarity with a polynucleotide coding for a polypeptide with the transcription factor function and having an amino acid sequence homologous with the sequence SEQ ID N°3.
 - 10 b) a complementary polynucleotide of polynucleotide a).
 - c) a polynucleotide comprising at least 15 consecutive bases of the polynucleotide defined in a) and b).
- 2) Polynucleotide according to claim 1 in that this polynucleotide is a DNA.
- 15 3) Polynucleotide according to claim 1 in that this polynucleotide is an RNA.
- 4) Polynucleotide as defined in claim 2 comprising the nucleotide sequence SEQ ID N°1
- 5) DNA sequence as defined in claims 1, 2 and 4 characterized
 - 20 in that this DNA sequence is that of the CATfIIIA gene coding for a protein having the biological function of transcription factor of Candida albicans CATFIIIA containing the nucleotide sequence SEQ ID N°1
- 6) DNA sequence according to claim 5 having the sequence
 - 25 starting at nucleotide 720 and finishing at nucleotide 1955 of SEQ ID N°1.
- 7) DNA sequence of the CATfIIIA gene according to claim 5 or 6 coding for the amino acid sequence SEQ ID N°3 (412 AA).
- 8) DNA sequence coding for the transcription factor CATFIIIA
 - 30 according to claims 5 to 7 as well as DNA sequences which hybridize with it and/or have a significant homology with this sequence or fragments of it and having the same function.
- 9) DNA sequence according to claims 5 to 8 comprising
 - 35 modifications introduced by suppression, insertion and/or substitution of at least one nucleotide coding for a protein having the same biological activity as the transcription factor CATFIIIA.

- 10) DNA sequence according to one of claims 5 to 9 as well as the DNA sequences which have a nucleotide sequence homology of at least 50 % or at least 60 % and preferably at least 70 % with the said DNA sequence.
- 5 11) DNA sequence according to one of claims 5 to 10 as well as the DNA sequences which code for a protein with a similar function the AA sequence of which has a homology of at least 40 % and in particular 45 % or at least 50 %, rather at least 60 % and preferably at least 70 % with the AA sequence coded
- 10 by the said DNA sequence.
- 12) Polypeptide having the transcription factor function CATFIIIA and having the amino acid sequence SEQ ID N°3 coded by the DNA sequence according to one of claims 5 to 11 and the analogues of this polypeptide.
- 15 13) Process for the preparation of the recombinant protein CATFIII having the amino acid sequence SEQ ID N°3 comprising expression of the DNA sequence according to one of claims 5 to 11 in an appropriate host then isolation and purification of the said recombinant protein.
- 20 14) Expression vector containing the DNA sequence according to one of claims 5 to 11.
- 15) Host cell transformed with a vector according to claim 14.
- 16) Process as defined in claim 13 in which the host cell is
- 25 DH5 alpha E. coli or XL1-Blue E. coli.
- 17) Process as defined in claim 13 in which the host cell is ¹Saccharomyces cerevisae.
- 18) Plasmid deposited at the CNCM under the number I-2072.
- 19) Process of screening antifungal products characterized in
- 30 that it comprises a stage where the the transcription activity factor of CATFIIIA as defined in claim 12 is measured in the presence of each of the products the antifungal properties of which need to be determined and the products having an inhibitory effect on this activity are
- 35 selected.
- 20) Use of a product selected by the process according to claim 19 in order to obtain an antifungal agent.
- 21) Use of the gene of the transcription factor CATfIIIA of

Candida albicans or of the transcription factor coded by this gene according to one of claims 5 to 12 for the selection of a product with antifungal properties according to claim 19 as an inhibitor of the transcription factor of Candida albicans.

- 5 **22)** Pharmaceutical compositions containing as active ingredient at least one inhibitor of the transcription factor of Candida albicans as defined in claim 21.
- 23)** Use of compositions as defined in claim 22 as antifungal agents.
- 10 **24)** Method of inducing an immunological response in a mammal comprising the inoculation of this mammal with the polypeptide as defined in claim 12 or a fragment of this polypeptide having the same function in order to produce an antibody making it possible to protect the animal against the
- 15 disease.
- 25)** Antibody directed against the polypeptide as defined in claim 12 or a fragment of this polypeptide having the same function.
- 26)** Use of the CATfIIIA gene or of the transcription factor
- 20 coded by this gene according to one of claims 5 to 12 for the preparation of compositions which can be used for the diagnosis or the treatment of diseases caused by the pathogenic yeast Candida albicans.
- 27)** Kit for the diagnosis of fungal infections comprising a
- 25 DNA sequence as defined in one of claims 5 to 11 or a sequence having a similar function or a functional fragment of this sequence, the polypeptide coded by this sequence or a polypeptide fragment having the same function or an antibody directed against such a polypeptide coded by this DNA
- 30 sequence or against a fragment of this polypeptide.

**DECLARATION FOR
UTILITY OR DESIGN
PATENT APPLICATION**

Attorney Docket Number	146.1365
First Named Inventor	F. BORDON-PALLIER
COMPLETE IF KNOWN	
Application Number	PCT/FR99/02739
Filing Date	11/9/99
Group Art Unit	
Examiner Name	

☒ Declaration OR
Submitted
with Initial Filing

☐ Declaration
Submitted after
Initial Filing

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**CANDIDA ALBICANS TFIIIA GENE (CatfIIIA) AND THE CODED
CATFIIIA PROTEIN**

(Title of the Invention)

the specification of which

☐ is attached hereto
OR☒ was filed on (MM/DD/YYYY)

Nov. 9, 1999

as United States Application Number or PCT International

Application Number **PCT/FR99/02739** and was amended on (MM/DD/YYYY) (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365 (a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
98/14147	France	11/10/98	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
PCT/FR99/02739	France	11/9/99	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto.

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

[Page 1 of 5]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents and Trademarks, Washington, DC 20231

(January 1997)

Please type a plus sign (+) inside this box →


 Approved for use through 9/30/98 OMB 0651-0032
 Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Name	Registration Number	Name	Registration Number
Charles A. Muserlian	19,683		
Jordan B. Bierman	18,629		
Donald C. Lucas	31,275		
Bierman, Muserlian and Lucas	18,818		

☐ Additional registered practitioner(s) named on a supplemental sheet attached hereto.

Direct all correspondence to:

Name	Bierman, Muserlian and Lucas		
Address			
Address	600 Third Avenue		
City	New York	State	New York
		ZIP	10016
Country	U.S.A.	Telephone	(212) 661-8000
		Fax	(212) 661-8002

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:

☐ A petition has been filed for this unsigned inventor

Given Name	FLORENCE	Middle Initial		Family Name	BORDON-PALLIER	Suffix e.g. Jr.	
Inventor's Signature					Date	23 April 2001	

Residence: City	Guyancourt	State		Country	France	Citizenship	FR
Post Office Address							
Post Office Address	37, Boulevard Beethoven						
City	Guyancourt	State		Zip	F-78280	Country	France

☒ Additional inventors are being named on supplemental sheet(s) attached hereto



DECLARATION

ADDITIONAL INVENTOR(S)
Supplemental Sheet

Name of Additional Joint Inventor, if any:

☐ A petition has been filed for this unsigned inventor

Given Name	SYLVIE	Middle Initial		Family Name	CAMIER	Suffix	
------------	--------	----------------	--	-------------	--------	--------	--

Inventor's Signature	<i>Sylvie Camier</i>	Date	25 May 2001
----------------------	----------------------	------	-------------

Residence: City	Piemont	State	CA	Country	USA	Citizenship	FR/US
-----------------	---------	-------	----	---------	-----	-------------	-------

Post Office Address

Post Office Address 66, Oakmont Avenue

City	Piemont	State	CA	Zip	94610	Country	USA
------	---------	-------	----	-----	-------	---------	-----

Name of Additional Joint Inventor, if any:

☐ A petition has been filed for this unsigned inventor

Given Name	ANDRE	Middle Initial		Family Name	SENTENAC	Suffix	
------------	-------	----------------	--	-------------	----------	--------	--

Inventor's Signature	<i>A. Sentenac</i>	Date	4 Mai 2001
----------------------	--------------------	------	------------

Residence: City	Gif sur Yvette	State		Country	France FR X	Citizenship	FR
-----------------	----------------	-------	--	---------	-------------	-------------	----

Post Office Address Service de Biochimie et Genetique Moleculaire Bat

Post Office Address 142 CEA/SACLAY

City	Gif sur Yvette	State		Zip	FR-91191	Country	France
------	----------------	-------	--	-----	----------	---------	--------

Name of Additional Joint Inventor, if any:

☐ A petition has been filed for this unsigned inventor

Given Name		Middle Initial		Family Name		Suffix	
------------	--	----------------	--	-------------	--	--------	--

Inventor's Signature		Date	
----------------------	--	------	--

Residence: City		State		Country		Citizenship	
-----------------	--	-------	--	---------	--	-------------	--

Post Office Address

Post Office Address

City		State		Zip		Country	
------	--	-------	--	-----	--	---------	--

Name of Additional Joint Inventor, if any:

☐ A petition has been filed for this unsigned inventor

Given Name		Middle Initial		Family Name		Suffix	
------------	--	----------------	--	-------------	--	--------	--

Inventor's Signature		Date	
----------------------	--	------	--

Residence: City		State		Country		Citizenship	
-----------------	--	-------	--	---------	--	-------------	--

Post Office Address

Post Office Address

City		State		Zip		Country	
------	--	-------	--	-----	--	---------	--

☐ Additional inventors are being named on supplemental sheet(s) attached hereto

SEQUENCE LISTING

<110> Hoechst Marion Roussel

<120> Candida albicans tfIIIA gene (CATfIIIA) and the coded CATfIIIA protein.

<130> PATENT 9824

<140>

<141>

<160> 9

<170> PatentIn. 2.0

<210> 1

<211> 2060

<212> DNA

<213> Candida albicans

<400> 1

```

ctttattagg aagattggct aggccatttt gtattacggg tctccaaagt gcaattgttt 60
tagtaaatat ccaatcattg ggcttcagtg tgaatggggg ttgtcaatct cttggtgtag 120
aaataggcgc aggccctccga atcccaaaaa aagaagaatc aggatgtctc ggctgcaaga 180
tttgtagcca tggcaaatgc cgaaaaatga aaaaaaaaaa aaagtctact gggcccacct 240
acaaaaggaa aagtgattga actagatcag tagtgggtctg gaccctctat aattttataa 300
tattgtcacg ggctttagaa tttgtataat tgtgtgtctg acactctgtg gttaatatct 360
ggacatctcg ttccccctgt gaagggtcgt ctgtaatgaa ttcgatgatca agaataatat 420
gactttgctc acttcataga gtgcgcgactt gattattatt gagctttatc ctctgtaata 480
tatcgtaacc acttgactta tttccttggt gtgggattca ctttggatga tgatgttaac 540
caaatgtaat tggtaacaat ctttttgtcc ttgtcgcgac ttcccttaat atcgcgactt 600
atttcattaa tgagacgcaa cgcattcctc tctccataga aaaaaaaaaa acaaaactga 660
aaaaataaac agcggacctc atctcttttt ttcaaataca ctttttatta ctttattcaa 720
tgagtgaag tgacgaaacc aaatcgatat catctttaat atcttcttct tottcatcac 780
gtcccaaaaa gtatatattgc acatatgaag ggtgtgataa agcctataat cgaccatcat 840
tattagagca acatttaaga acccacagta atgatcgacc gtataaatgt acagtggacg 900
attgtgataa agcatttttc agaaaatcac atttgaaaac acatattgta tcacattccg 960
aaaaaaaaac attccattgt tcagtgtgtg gtaaaggggt taattctcga caaacattga 1020
aaagacatga aatcacccat acaaagtcac ttaaagtac atttgaaaat tgtcaagaag 1080
cattttataa acatcaatct ttaagacatc atatattatc tgttcatgaa aaaacattaa 1140
cgtgtaaaaa atgtaataaa gttttcactc gaccttcaaa attagcacia cataaattaa 1200
aacatcatgg tggatctcct gcttatcaat gtgatcatcc tggttgtttt aaaaatttcc 1260
aaacttggtc agtattacaa tttcatataa aacaactgca tccaaaactt aaatgtccta 1320

```

09/831804

```
<210> 2
<211> 1239
<212> DNA
<213> Candida albicans
```

<400> 2																	
atg agt gaa agt gac gaa acc aaa tcg ata tca tct tta ata tct tct																48	
Met Ser Glu Ser Asp Glu Thr Lys Ser Ile Ser Ser Leu Ile Ser Ser																	
1					5					10					15		
tct tct tca tca cgt ccc aaa aag tat att tgc aca tat gaa ggg tgt																96	
Ser Ser Ser Ser Arg Pro Lys Lys Tyr Ile Cys Thr Tyr Glu Gly Cys																	
	20				25				30								
gat aaa gcc tat aat cga cca tca tta tta gag caa cat tta aga acc																144	
Asp Lys Ala Tyr Asn Arg Pro Ser Leu Leu Glu Gln His Leu Arg Thr																	
	35				40				45								
cac agt aat gat cga ccg tat aaa tgt aca gtg gac gat tgt gat aaa																192	
His Ser Asn Asp Arg Pro Tyr Lys Cys Thr Val Asp Asp Cys Asp Lys																	
	50				55				60								
gca ttt ttc aga aaa tca cat ttg gaa aca cat att gta tca cat tcc																240	
Ala Phe Phe Arg Lys Ser His Leu Glu Thr His Ile Val Ser His Ser																	
65					70				75				80				
gaa aaa aaa cca ttc cat tgt tca gtg tgt ggt aaa ggg gtt aat tct																288	
Glu Lys Lys Pro Phe His Cys Ser Val Cys Gly Lys Gly Val Asn Ser																	
	85								90				95				
cga caa cac ttg aaa aga cat gaa atc acc cat aca aag tca ttt aaa																336	
Arg Gln His Leu Lys Arg His Glu Ile Thr His Thr Lys Ser Phe Lys																	
	100				105				110								

tgt Cys	aca Thr	ttt Phe 115	gaa Glu	aat Asn	tgt Cys	caa Gln	gaa Glu 120	gca Ala	ttt Phe	tat Tyr	aaa Lys	cat His 125	caa Gln	tct Ser	tta Leu	384
aga Arg	cat His 130	cat His	ata Ile	tta Leu	tct Ser	gtt Val 135	cat His	gaa Glu	aaa Lys	aca Thr	tta Leu 140	acg Thr	tgt Cys	aaa Lys	caa Gln	432
tgt Cys 145	aat Asn	aaa Lys	gtt Val	ttc Phe	act Thr 150	cga Arg	cct Pro	tca Ser	aaa Lys	tta Leu 155	gca Ala	caa Gln	cat His	aaa Lys	tta Leu 160	480
aaa Lys	cat His	cat His	ggg Gly 165	gga Gly	tct Ser	cct Pro	gct Ala	tat Tyr	caa Gln 170	tgt Cys	gat Asp	cat His	cct Pro	ggg Gly 175	tgt Cys	528
ttt Phe	aaa Lys	aat Asn	ttc Phe 180	caa Gln	act Thr	tgg Trp	tca Ser	gta Val 185	tta Leu	caa Gln	ttt Phe	cat His	ata Ile 190	aaa Lys	caa Gln	576
ctg Ser	cat His	cca Pro 195	aaa Lys	ctt Leu	aaa Lys	tgt Cys	cct Pro 200	aaa Lys	tgt Cys	ggg Gly	aaa Lys	ggg Gly 205	tgt Cys	gtt Val	ggg Gly	624
aaa Lys 210	aaa Lys	ggg Gly	tta Leu	tct Ser	tca Ser	cat His 215	atg Met	tta Leu	agt Ser	cat His	gat Asp 220	gat Asp	tct Ser	acc Thr	atg Met	672
atc Ile 225	aaa Lys	ata Ile	tgg Trp	act Thr	tgt Cys 230	gat Asp	tat Tyr	tgt Cys	gat Asp	gtg Val 235	ggg Gly	aaa Lys	ttt Phe	gca Ala	aag Lys 240	720
aaa Lys	aat Asn	gaa Glu	tta Leu	gtt Val 245	gaa Glu	cat His	tat Tyr	aat Asn	atc Ile 250	ttc Phe	cat His	gat Asp	ggg Gly	aat Asn 255	atc Ile	768
cct Pro	gat Asp	gat Asp	tta Leu 260	tta Leu	aag Lys	gaa Glu	act Thr	gaa Glu 265	gtg Val	aaa Lys	aaa Lys	tta Leu	gag Glu 270	aac Asn	cta Leu	816
tta Leu	gat Asp	caa Gln 275	gga Gly	tcg Ser	aaa Lys	tta Leu	aat Asn 280	aat Asn	ttg Leu	cat His	gaa Glu 285	tta Leu	gaa Glu	aca Thr	gag Glu	864
aaa Lys	tta Leu 290	aaa Lys	gtg Val	gaa Glu	gaa Glu	gat Asp 295	gaa Glu	gaa Glu	gat Asp	gaa Glu 300	gaa Glu	gat Asp	agt Ser	cta Leu	gat Asp	912
gaa Glu 305	aaa Lys	aga Arg	agt Ser	gat Asp	gtt Val 310	aga Arg	tca Ser	gac Asp	tca Ser	atg Met 315	tca Ser	gct Ala	caa Gln	aga Arg	tca Ser 320	960
ata Ile	aaa Lys	tca Ser	ttt Phe	act Thr 325	gct Ala	tct Ser	ttg Leu	gaa Glu	ggg Gly 330	tca Ser	aag Lys	agt Ser	gtt Val 335	tct Ser	aaa Lys	1008
ctt Leu	att Ile	ctg Ser	aat Asn 340	agt Ser	ggg Gly	aag Lys	aag Lys	atc Ile 345	aat Asn	tgt Cys	cct Pro	aag Lys	aat Asn 350	aat Asn	tgt Cys	1056
gat Asp	aga Arg	atg Met 355	ttt Phe	tct Ser	aga Arg	gaa Glu	tat Tyr 360	gat Asp	tta Leu	cgt Arg	cga Arg	cat His 365	ttg Leu	aaa Lys	tgg Trp	1104

cat	gat	gat	aat	tta	caa	aga	att	gag	tca	ttc	tta	aat	agt	ata	gaa	1152
His	Asp	Asp	Asn	Leu	Gln	Arg	Ile	Glu	Ser	Phe	Leu	Asn	Ser	Ile	Glu	
	370					375					380					
aaa	gaa	gaa	act	cca	gaa	ggg	gaa	cca	ttg	gtt	aaa	aaa	gcc	agg	atg	1200
Lys	Glu	Glu	Thr	Pro	Glu	Gly	Glu	Pro	Leu	Val	Lys	Lys	Ala	Arg	Met	
	385				390					395					400	
gat	tta	ttg	cca	aat	gaa	aca	tca	gtg	att	tct	cga	taa				1239
Asp	Leu	Leu	Pro	Asn	Glu	Thr	Ser	Val	Ile	Ser	Arg					
				405					410							
<210> 3																
<211> 412																
<212> PRT																
<213> Candida albicans																
<400> 3																
Met	Ser	Glu	Ser	Asp	Glu	Thr	Lys	Ser	Ile	Ser	Ser	Leu	Ile	Ser	Ser	
1				5					10					15		
Ser	Ser	Ser	Ser	Arg	Pro	Lys	Lys	Tyr	Ile	Cys	Thr	Tyr	Glu	Gly	Cys	
			20					25					30			
Asp	Lys	Ala	Tyr	Asn	Arg	Pro	Ser	Leu	Leu	Glu	Gln	His	Leu	Arg	Thr	
		35					40					45				
His	Ser	Asn	Asp	Arg	Pro	Tyr	Lys	Cys	Thr	Val	Asp	Asp	Cys	Asp	Lys	
	50					55					60					
Ala	Phe	Phe	Arg	Lys	Ser	His	Leu	Glu	Thr	His	Ile	Val	Ser	His	Ser	
	65				70					75					80	
Glu	Lys	Lys	Pro	Phe	His	Cys	Ser	Val	Cys	Gly	Lys	Gly	Val	Asn	Ser	
				85					90					95		
Arg	Gln	His	Leu	Lys	Arg	His	Glu	Ile	Thr	His	Thr	Lys	Ser	Phe	Lys	
			100					105					110			
Cys	Thr	Phe	Glu	Asn	Cys	Gln	Glu	Ala	Phe	Tyr	Lys	His	Gln	Ser	Leu	
		115					120					125				
Arg	His	His	Ile	Leu	Ser	Val	His	Glu	Lys	Thr	Leu	Thr	Cys	Lys	Gln	
	130					135					140					
Cys	Asn	Lys	Val	Phe	Thr	Arg	Pro	Ser	Lys	Leu	Ala	Gln	His	Lys	Leu	
145					150					155					160	
Lys	His	His	Gly	Gly	Ser	Pro	Ala	Tyr	Gln	Cys	Asp	His	Pro	Gly	Cys	
			165						170					175		
Phe	Lys	Asn	Phe	Gln	Thr	Trp	Ser	Val	Leu	Gln	Phe	His	Ile	Lys	Gln	
			180					185					190			
Ser	His	Pro	Lys	Leu	Lys	Cys	Pro	Lys	Cys	Gly	Lys	Gly	Cys	Val	Gly	
		195					200					205				
Lys	Lys	Gly	Leu	Ser	Ser	His	Met	Leu	Ser	His	Asp	Asp	Ser	Thr	Met	
	210					215					220					
Ile	Lys	Ile	Trp	Thr	Cys	Asp	Tyr	Cys								

Pro Asp Asp Leu Leu Lys Glu Thr Glu Val Lys Lys Leu Glu Asn Leu
 260 265 270
 Leu Asp Gln Gly Ser Lys Leu Asn Asn Leu His Glu Leu Glu Thr Glu
 275 280 285
 Lys Leu Lys Val Glu Glu Asp Glu Glu Asp Glu Asp Ser Leu Asp
 290 295 300
 Glu Lys Arg Ser Asp Val Arg Ser Asp Ser Met Ser Ala Gln Arg Ser
 305 310 315 320
 Ile Lys Ser Phe Thr Ala Ser Leu Glu Gly Ser Lys Ser Val Ser Lys
 325 330 335
 Leu Ile Ser Asn Ser Gly Lys Lys Ile Asn Cys Pro Lys Asn Asn Cys
 340 345 350
 Asp Arg Met Phe Ser Arg Glu Tyr Asp Leu Arg Arg His Leu Lys Trp
 355 360 365
 His Asp Asp Asn Leu Gln Arg Ile Glu Ser Phe Leu Asn Ser Ile Glu
 370 375 380
 Lys Glu Glu Thr Pro Glu Gly Glu Pro Leu Val Lys Lys Ala Arg Met
 385 390 395 400
 Asp Leu Leu Pro Asn Glu Thr Ser Val Ile Ser Arg
 405 410

<210> 4
 <211> 21
 <212> DNA
 <213> Candida albicans

<400> 4
 atgagtgaaa gtagcgaac c 21

<210> 5
 <211> 24
 <212> DNA
 <213> Candida albicans

<400> 5
 attggaatgg ttttttttcg gaat 24

<210> 6
 <211> 23
 <212> DNA
 <213> Candida albicans

<400> 6
 tggtttcgtc actttcactc att 23

<210> 7
 <211> 25
 <212> DNA
 <213> Candida albicans

<400> 7

25


<213> Candida albicans

27

<213> Candida albicans

27

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



SCANNED, # 2

Application deficiencies found during scanning:

☒ Page(s) 4-5 of 5 of Declaration _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ *Scanned copy is best available.*